Goldman Sachs to keep investment on Korean firms

Published: 2012-12-10 07:00:00

Updated: 2012-12-10 07:00:00

With its renewed interest in Korean firms, Goldman Sachs said it will not withdraw any investment from Geoyoung, despite the previous announcement that it is shutting down its Korean operation.

According to industry insiders, Goldman Sachs is likely to terminate some of its funds while other a...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK